CUVL CUVL
Company Profile ↓Company Overview
CUVL (CUVL) is a publicly traded company listed on with a market capitalization of $325.80M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 15.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 18.7%.
Net profit has compounded at 20.1% per year over the last five years.
Revenue has grown at a 13.1% CAGR over the past five years.
Trades at an undemanding P/E of 9.1.
Maintains a net profit margin of 38.1%.
Recent Developments
- Jun 2025 Revenue of $95.02M (+7.8% YoY); net profit $36.17M.
- Trailing 12 Months Year-on-year growth — revenue +7.8%, earnings +1.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.1%, profit CAGR 20.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.07% |
| 1 Year: | 7.76% |
Compounded Profit Growth
| 5 Years: | 20.10% |
| 1 Year: | 1.50% |
Stock Price Performance
| 1 Year: | -17.88% |
| 6 Months: | -18.60% |
| 3 Months: | -7.87% |
| 1 Month: | -10.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 38.1%.
- Compounding revenue at 13.1% over 5 years.
- Profit CAGR of 20.1% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 25.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 65.72M | 78.32M | 88.18M | 95.02M |
| Cost of Revenue | 10.48M | 8.79M | 10.08M | 15.88M |
| Gross Profit | 55.24M | 69.53M | 78.10M | 79.14M |
| Operating Expenses | 19.91M | 25.43M | 30.09M | 33.40M |
| Operating Income | 35.33M | 44.10M | 48.01M | 45.73M |
| EBITDA | 37.35M | 49.56M | 56.28M | 57.20M |
| Interest Expense | 2.27M | 3.19M | 4.45M | 4.46M |
| Pretax Income | 34.32M | 45.58M | 50.68M | 51.55M |
| Tax Provision | 13.44M | 14.97M | 15.04M | 15.38M |
| Net Income | 20.88M | 30.60M | 35.64M | 36.17M |
| Diluted EPS | 0.40 | 0.59 | 0.70 | 0.72 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 143.95M | 193.71M | 231.12M | 271.75M |
| Current Assets | 140.58M | 189.62M | 222.06M | 262.97M |
| Cash & Equivalents | 121.51M | 156.81M | 183.87M | 224.11M |
| Inventory | 1.83M | 9.52M | 10.63M | 8.82M |
| Receivables | 15.90M | 20.81M | 25.16M | 24.32M |
| Total Liabilities | 18.39M | 29.08M | 28.11M | 30.94M |
| Current Liabilities | 13.73M | 25.49M | 25.21M | 27.21M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.26M | 999.87K | 879.78K | 528.53K |
| Total Equity | 125.56M | 164.63M | 203.01M | 240.81M |
| Shares Outstanding | 49.41M | 49.41M | 50.08M | 50.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - |
| Investing Cash Flow | -434.44K | -1.03M | -29.03M | -47.72M |
| Financing Cash Flow | -1.50M | -2.24M | -3.57M | -2.94M |
| Capital Expenditure | -434.44K | -1.03M | -5.58M | -298.57K |
| Free Cash Flow | 39.44M | 35.88M | 31.48M | 40.80M |
| Net Change in Cash | 37.93M | 33.64M | 4.45M | -9.56M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | 84.0% | 88.8% | 88.6% | 83.3% |
| Operating Margin % | 53.8% | 56.3% | 54.4% | 48.1% |
| Net Margin % | 31.8% | 39.1% | 40.4% | 38.1% |
| ROE % | 16.6% | 18.6% | 17.6% | 15.0% |
| ROCE % | 27.1% | 26.2% | 23.3% | 18.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CUVL
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFB6NWV0TlhJMXNabkh0Z3phWUJrM29BejNicDlRSnhkd2IwdUhya2pydkQtRG1sdWtYc1dtREhwQUFUaDVZYkFHSFFDa0FYWkhU?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
CUVL | Clinuvel Pharmaceuticals Limited American Institutional Ownership - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTE1sNXRmV1FLQzNzSEo5cjM3TTAtUEhuTUV4dXdxOTk4Z1R4Mld3cEFkTHdRQmotdkNfaWFnSlZBNEhwRVBxd3huVWRNc0huWFVZeFc2S0xGSHp5Q0JBZXJobVhB?oc=5" target="_blank">CUVL | Clinuvel Pharmaceuticals Lim…
CLINUVEL to Pivot Operations to U.S. Pipeline; About 6M Affected by Vitiligo - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQUXA1Wk81OEpoMm5UYVN4ODVHYzAxMDE1ZGppYXViaU5vWGhJOFBkNmJ1UGctX0FzU2kyR2dkZjhyZUZKWVVPSkJ6YmFObjJXeHlxTU52NWpzVnlCOHd5a09uWmo4dnR2YWJEVUxMRlc2ZkV0bE5xTTJwVlMwR3RrQzlvTEJUdmJRSmh2dU…
CLINUVEL’s ADS to commence trading on Nasdaq - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPQkJxT2dNVWRScG1uT0xxYjU1dGs2R0VlOVhCS21Wal9mY1VsNkZPcHNUc1BSVHZmcUhOd2lXeGdyd0RveXI2dHFQSUVDR0dJVnJDc0RtT3NpbzNyNl94OEpWUUQxcFBNS2xGVmlHTlNlSE5mMUUzYXZlLXhMLUVXNEdpMDNSSFB0ZEN4em…
CUVL: NA - 12 Month EPS - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPcFExZTNRaFg3eDlGY3Fwc3cxR0ZBb2Z5NGN2Vnh3UVFBNldlU2FXdzA1aHloY1J5eV92OXVhRm50LWZrMVF2cWE2RmtYTlBra01jeUs1MXZKUTR5eW50VHRxRmRFZFlhSV9sc2Y3cHdGYmpuUFIxNFpiOVJxeXpQd2ZIc0JFT2p4UzJ6Zm…
Clinuvel Starts Trading Level II ADS on Nasdaq Under CUVL - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQQVJ6RWl0Y1Rlb3dyN1FkeDE4YmJEWEpsUl9NSmdOYWlScDNnTXpncHBtMl81N0cxMk90Wkk1cUxISGlIWE0wZEUyRE9mTXA3UkhZUm54RHc5MXVTMXlKeWUyU0xwNzBtQ1Q1OVpPcm5sRkRST2FjVDVUcUtuQmpBMklkTXVKUzVRQnBXX0…
CUVL — Frequently Asked Questions
What is the current share price of CUVL?
As of 2026-08-05 17:25 PDT, CUVL trades at $6.50 on NASDAQ/NYSE. Its 52-week range is $6.19 to $8.76.
What is the market capitalisation of CUVL?
CUVL has a market capitalisation of $325.80M on NASDAQ/NYSE.
What is the P/E ratio of CUVL?
CUVL trades at a trailing price-to-earnings (P/E) ratio of 9.05. Its price-to-book (P/B) ratio is 1.35.
What is the return on equity (ROE) of CUVL?
CUVL has a return on equity (ROE) of 15.02%. Its return on capital employed (ROCE) is 18.70%.
Is CUVL a good stock to buy?
This page provides a data-driven analysis of CUVL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.